NVCT logo

NUVECTIS PHARMA INC

NVCTNASDAQ
🏆 #2781 by market capUS Equity
$391.55▼ $6.62 (−1.69%)
Simulated price
🔔
Track NVCT
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.7%
7d▲ 1603.1%
14d▲ 1676.9%
30d▲ 1558.4%
ytd▲ 5028.4%
1y▲ 6486.2%
🏦Market Cap
$660M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
68
Fair

Trading Snapshot

Day Range
$387.74 – $397.24
52-Week Range
$5.55 – $29.28
Volume
$2.34B
Avg Volume
$2.87B
Shares Outstanding
31.5M
Next Earnings
Nov 29, 2026

Fundamentals Snapshot

Annual Revenue
$330M
Last Q Revenue
$78M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-1.20
Dividend Yield
—
Dilution (1yr)
+11.9%

Why Investors Own NVCT

  • ✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 54% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NVCT logo

NUVECTIS PHARMA INC

NVCT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$28M▲ +38.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$16M▲ +30.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21.8M▲ +11.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$32M▲ +$13M YoY
StockOtter · stockotter.space

About NUVECTIS PHARMA INC

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$456.43
▲ +16.6% Upside
High Target$558.77
Low Target$385.16
Based on 16 analysts

Latest News & Updates

🚀
CNBC·2h ago

NUVECTIS PHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift NVCT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

NUVECTIS PHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.